Here are the S-3 shelf registrations from Arcadia Biosciences, Inc. (RKDA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow RKDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKDA filings page.
Arcadia Biosciences, Inc. registers for resale up to 11,922,333 shares of Common Stock on a resale basis, consisting of shares issuable upon exercise of pre-funded warrants, preferred investment options and placement agent options. The registrant will not receive proceeds from resales, but would receive proceeds upon any cash exercise of the Options.
The prospectus states 2,181,715 shares outstanding before this offering (as of June 23, 2026) and, assuming full exercise of the Options, 14,104,048 shares outstanding after issuance. If all Options were exercised for cash, gross proceeds to the company would be approximately $7.4 million. The prospectus discloses a Nasdaq closing price of $0.6889 on June 24, 2026.
Arcadia Biosciences, Inc. is registering up to 1,673,792 shares of common stock for resale by selling stockholders. These shares are issuable upon exercise of preferred investment options issued in a January 2026 warrant inducement private placement, including investment options and placement agent options.
The company will not receive proceeds from resale of these shares, but could receive up to approximately $3.94 million if all options are exercised for cash, which it plans to use for working capital and general corporate purposes. Shares outstanding were 1,729,884 as of January 23, 2026, and would be 3,403,676 if all option shares under this prospectus are issued.
Arcadia has shifted from agricultural traits to consumer products and now focuses on its Zola coconut water brand after selling key wheat and GoodWheat assets in 2024. The filing highlights substantial doubt about the company’s ability to continue as a going concern and a need for additional near-term financing. A planned all-stock business combination with Roosevelt Resources was terminated in December 2025, so no merger will proceed under that agreement. The company describes this investment as high risk and notes potential dilution and stock price pressure if large blocks of newly issuable shares are sold.